Resurrect Bio, which operates from Norwich Research Park, uses Artificial Intelligence (AI) to identify and resurrect disease resistance genes in plants that have been suppressed by pathogens, which are disease-causing microorganisms.

Resurrect Bio operates from both Norwich Research Park and London (Image: Supplied)

The process involves making small changes to a plant’s genes, restoring the crop’s ability to defend itself against bacteria, viruses and fungi.

It aims to help farmers protect yields against diseases that pose a threat to global food security.

Dr Cian Duggan, CEO of Resurrect Bio, said: "We're thrilled to have secured this investment from such a distinguished group of partners who share our vision of delivering durable disease resistance to farmers.

Dr Cian Duggan, CEO of Resurrect Bio (Image: Supplied)

"With Corteva's leadership and the support of Calculus Capital, Pymwymic and our existing investors, we're now positioned to scale our platform and deliver multiple resistance traits to the seed industry."

Roz Bird, CEO of Anglia Innovation Partnership, the campus management company for Norwich Research Park, added: “This is great news for Resurrect Bio and a really good indicator that Norwich Research Park is being recognised as a hotbed for innovation that is attracting serious investors.

"Companies based on our campus have already passed the £100 million milestone in funds they have attracted, and we can expect more investments of this type as new companies emerge from our incubator programme and from our soon-to-be-launched accelerator programme.

"Investors both nationally and internationally are beginning to acknowledge that Norwich is a very opportunistic place for them to invest, which is good news for companies based here as it is for the future Norfolk economy."

© Norwich Evening News